Statements (56)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:Company
|
| gptkbp:administrativeDivision |
once daily
|
| gptkbp:affiliatedWith |
other antiretrovirals
|
| gptkbp:approves |
gptkb:FDA
|
| gptkbp:availability |
prescription only
|
| gptkbp:availableIn |
generic form
|
| gptkbp:careInstructions |
first-line therapy
|
| gptkbp:clinicalTrials |
Phase III
recommended in treatment guidelines long-term management of HIV |
| gptkbp:contains |
emtricitabine
tenofovir disoproxil fumarate efavirenz |
| gptkbp:contraindication |
liver toxicity
hypersensitivity to components kidney toxicity neuropsychiatric symptoms |
| gptkbp:diseaseResistance |
possible with non-adherence
|
| gptkbp:dosageForm |
fixed-dose combination
|
| gptkbp:drugInterdiction |
available online
once daily dosing |
| gptkbp:evaluates |
immune system recovery
viral load suppression |
| gptkbp:formFactor |
oral tablet
|
| gptkbp:formulation |
single tablet regimen
|
| gptkbp:hasPopulation |
adults
children over 12 years old |
| gptkbp:healthcare |
important for efficacy
recognizing side effects importance of adherence |
| https://www.w3.org/2000/01/rdf-schema#label |
Atripla
|
| gptkbp:interactsWith |
CYP450 inducers
CYP450 inhibitors |
| gptkbp:is_monitored_by |
liver function tests
renal function tests |
| gptkbp:isTaskedWith |
gptkb:St._John's_Wort
certain antibiotics certain antifungals certain anticonvulsants |
| gptkbp:lastProduced |
2006
|
| gptkbp:manufacturer |
gptkb:Bristol-Myers_Squibb
|
| gptkbp:marketedAs |
gptkb:ATRIPLA
|
| gptkbp:offers |
varies by region
|
| gptkbp:patentExpiration |
2020
|
| gptkbp:research |
ongoing studies on long-term effects
studies on drug interactions studies on resistance patterns |
| gptkbp:safety |
pregnancy category D
|
| gptkbp:sideEffect |
dizziness
nausea rash insomnia |
| gptkbp:storage |
room temperature
|
| gptkbp:triggerType |
non-nucleoside reverse transcriptase inhibitor
nucleotide reverse transcriptase inhibitor |
| gptkbp:usedFor |
treatment of HIV
|